ArticleiScience2025
Regulatory role of phosphatidylcholine metabolic reprogramming in colorectal cancer progression and neutrophil interactions.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integration of clinical and cellular lipidomics identifies a serum metabolite signature predictive of oxaliplatin resistance in colorectal cancer.Functional & integrative genomics · 2026Article
- N-acetylcysteine modulates neutrophil-driven immune and metabolic pathways in steatotic liver ischemia-reperfusion injury.Frontiers in immunology · 2026Article
- Targeted plasma lipidomics in non-metastatic colorectal cancer, metastatic colorectal cancer, and healthy controls: an exploratory matched-triplet study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a significant global health challenge due to its high incidence, mortality, and persistent issues with drug resistance, recurrence, and metastasis. Lipid metabolism reprogramming-a hallmark of CRC-plays a critical role in tumor progression. Mendelian randomization analysis established a causal relationship between phosphatidylcholine (PC) metabolism and CRC. Integrative analyses of transcriptomic and lipidomic data demonstrated that elevated PC levels are linked to enhanced CRC proliferation, metastasis, drug resistance, and increased tumor-associated neutrophils (TANs) infiltration. Machine-learning-based diagnostic and prognostic models underscore the clinical significance of PC-metabolism-related genes, identifying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.